DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. An investigational oral drug lowered lipoprotein(a) ...

The U.S. Food and Drug Administration (FDA) on Monday cleared the amendment to Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug (IND) application for the Phase 1b/2 trial of LP-184 in a ...

CHICAGO, IL—Two new drugs targeting lipoprotein(a)—one a small interfering RNA (siRNA), the other an oral agent that prevents its formation—both showed positive results in early phase II studies, with ...

LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from its ...

Biomarker-activated cancer drug-candidate LP-184 demonstrates encouraging efficacy signals in DNA damage repair deficient tumors with an acceptable safety and tolerability profile – meeting all ...

All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profile Statistically significant improvements achieved across all efficacy endpoints at the 4-week ...

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI)-driven oncology company leveraging its proprietary RADR® platform to accelerate targeted cancer ...